LUNGLIFE AI INC. DL-0001 (F:9H4) — Market Cap & Net Worth
Market Cap & Net Worth: LUNGLIFE AI INC. DL-0001 (9H4)
LUNGLIFE AI INC. DL-0001 (F:9H4) has a market capitalization of $1.06 Million (€904.73K) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #30169 globally and #2659 in its home market, demonstrating a -6.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LUNGLIFE AI INC. DL-0001's stock price €0.03 by its total outstanding shares 30658600 (30.66 Million).
LUNGLIFE AI INC. DL-0001 Market Cap History: 2022 to 2025
LUNGLIFE AI INC. DL-0001's market capitalization history from 2022 to 2025. Data shows change from $34.23 Million to $1.24 Million (-70.70% CAGR).
LUNGLIFE AI INC. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LUNGLIFE AI INC. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9H4 by Market Capitalization
Companies near LUNGLIFE AI INC. DL-0001 in the global market cap rankings as of May 5, 2026.
Key companies related to LUNGLIFE AI INC. DL-0001 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
LUNGLIFE AI INC. DL-0001 Historical Marketcap From 2022 to 2025
Between 2022 and today, LUNGLIFE AI INC. DL-0001's market cap moved from $34.23 Million to $ 1.24 Million, with a yearly change of -70.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €1.24 Million | -63.10% |
| 2024 | €3.35 Million | -87.19% |
| 2023 | €26.17 Million | -23.56% |
| 2022 | €34.23 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of LUNGLIFE AI INC. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.06 Million USD |
| MoneyControl | $1.06 Million USD |
| MarketWatch | $1.06 Million USD |
| marketcap.company | $1.06 Million USD |
| Reuters | $1.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LUNGLIFE AI INC. DL-0001
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more